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The Captain of the Men of Death and His Shadow: 
Long-Run Impacts of Early Life Pneumonia Exposure
* 
 
We exploit the introduction of sulfa drugs in 1937 to identify the causal impact of exposure to 
pneumonia in infancy on later life well-being and productivity in the United States. Using 
census data from 1980-2000, we find that cohorts born after the introduction of sulfa 
experienced increases in schooling, income, and the probability of employment, and 
reductions in disability rates. These improvements were larger for those born in states with 
higher pre-intervention levels of pneumonia as these were the areas that benefited most from 
the availability of sulfa drugs. These estimates are, in general, larger and more robust to 
specification for men than for women. With the exception of cognitive disability and poverty 
for men, the estimates for African Americans are smaller and less precisely estimated than 
those for whites. This is despite our finding that African Americans experienced larger 
absolute reductions in pneumonia mortality after the arrival of sulfa. We suggest that pre-Civil 
Rights barriers may have inhibited their translating improved endowments into gains in 
education and employment. 
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Infections are the leading cause of child mortality in developing countries, as they 
were in developed nations until the middle of the 20th century (Cohen, 2000; Black et al., 
2010). While this is well established, there is relatively limited (causal) evidence of the impact 
of infectious disease on survivors. Recent epidemiological studies suggest mechanisms by 
which exposure to infectious disease in early childhood may generate long run impacts. In 
essence, infection generates an inflammatory immune response that diverts nutritional 
resources away from physical and mental development. In this way, severe or repeated 
infections can directly lead to long-term “scarring” in the form of poorer health and lower 
cognitive development in adulthood (Crimmins and Finch, 2004; Crimmins and Finch, 
2006b; Eppig et al., 2010). In addition, if there are dynamic complementarities in early age 
inputs (Cunha and Heckman, 2007; Glewwe and Miguel, 2008), and if parents tend to 
reinforce changes in early life endowments, any particular damage in infancy may translate 
into multiplicative deficits later in childhood and into adulthood. These processes suggest 
that wellbeing and productivity in today’s population may, to a degree, have their roots in 
disease and treatment conditions that prevailed a generation or more ago.  
This paper investigates whether early life, in particular birth year, exposure to 
pneumonia has impacts on disability, human capital and productivity in adulthood. The 
setting is early 20
th century America, when pneumonia accounted for 1 of every 10 deaths 
and, barring mortality from premature birth, was the leading cause of infant mortality 
(Linder and Grove, 1947; Wegman, 2001). The ubiquity and ruthlessness of the disease led 
the great physician Sir William Osler to coin pneumonia as the “Captain of the Men of 
Death.” The Captain reigns in today’s developing countries, with pneumonia being the 
dominant cause of childhood mortality, accounting for 20 to 30 per cent of under-5 deaths, 
two thirds of which occur in infancy (Bhutta, 2007; Black et al., 2010). It is estimated that 
pneumonia kills 1.6 million children every year – more than AIDS, malaria and tuberculosis 
combined (World Health Organization, 2010).
1 We study birth year exposure in view of 
evidence that morbidity and mortality from pneumonia were far more prevalent in infancy 
                                                 
1 Yet AIDS, malaria and tuberculosis have generally commanded more attention from global health 
experts and policymakers. For example, the World Health Organization Commission on 
Macroeconomics and Health chaired by Jeffrey Sachs made the case for a Global Health Fund to 
fight these diseases. Pneumonia has more recently commanded public policy attention. This is 
discussed further in the Conclusions of the paper.   
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than at any other age. Moreover, infancy is a time when growth is rapid, nutritional demands 
are high, and developmental plasticity is greatest. For these reasons, exposure in the birth 
year is most likely to create irreversible damage.  
Identification of causal effects of early life infections on later life attainments is 
challenged by likely selectivity into infection. We overcome this problem by investigating the 
impacts of declines in pneumonia driven by the arrival of sulfonamide antibiotics (sulfa 
drugs) in 1937. These agents were the first clinically available antibiotics and were quickly 
utilized to treat a variety of potentially fatal bacterial infections. Their arrival was responsible 
for sharp decreases in morbidity and mortality from pneumonia (Greengard et al., 1943; 
Lesch, 2007; Jayachandran et al., 2010). Together with the quasi-experimental cohort 
variation generated by the sudden and plausibly exogenous arrival of sulfa drugs, our 
research strategy exploits the fact that states most burdened by pneumonia in the pre-sulfa 
era experienced the largest declines upon the introduction of sulfa. We investigate whether 
this short-run pattern of sudden convergence starting in 1937/38 is mirrored in longer run 
outcomes such as education, income, employment and disability recorded for sulfa cohorts 
in Unites States census data for 1980-2000. Our identification of causal effects is further 
strengthened by our use of variation across diseases in their sensitivity to sulfa drugs and 
variation across age in susceptibility to pneumonia. 
Our core findings are that cohorts exposed to sulfa drugs and thereby less 
pneumonia in the birth year, achieved large improvements in schooling, employment and 
income and lower risks of disability and poverty in adulthood. Importantly, these effects are 
largest for individuals born in states with high pre-intervention pneumonia mortality rates, 
consistent with their gaining more from the new antibiotics. The estimated gains for men are 
larger in magnitude and more robust to specification than for women. This is not an 
uncommon finding in the early childhood shocks literature (Stein et al., 2003; Crimmins and 
Finch, 2006a; van der Berg et al., 2007; Banerjee et al., 2010; Almond and Mazumder, 2011).  
The results are robust to controls for state-specific trends in health and education 
infrastructure, public health spending, income and a range of communicable and non-
communicable diseases that were not responsive to sulfa drugs. They are also robust to 
controlling for maternal mortality, which declined sharply after 1937 as a result of the sulfa 
drug revolution (Thomasson and Treber, 2008; Jayachandran et al., 2010). Using a more 
flexible specification that allows for differential impacts by age of exposure, we do not find  
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any noteworthy long run health or socioeconomic gains from reductions in pneumonia for 
cohorts born before 1937, who were at least a year old when sulfa drugs were first 
introduced. This is consistent with the epidemiology of pneumonia. We also conduct a 
variety of other robustness checks, including a triple difference specification exploiting the 
age distribution of pneumonia, a placebo intervention, changes in the cohort window used in 
estimation, and assessing the role of selective migration.  Our substantive conclusions hold 
up nicely to this slew of falsification checks.  
Since pneumonia infections were twice as prevalent amongst the poor as among the 
rich (Britten, 1942), our findings suggest that the narrowing of early life health inequalities 
induced by sulfa drugs led to a narrowing of socioeconomic inequalities half a century later. 
This complements evidence of the causality in the reverse direction, running from 
socioeconomic inequalities to health inequalities (Glied and Lleras-Muney, 2008). It suggests 
mechanisms that cycle into one another and hold the potential to generate intergenerational 
impacts to the extent that healthier children grow up to be richer adults and richer adults are 
better able to invest in the health of their offspring. Our estimates also establish that early 
life health improvements generate increased productivity. 
The gains we identify are not evenly distributed by race. Post-sulfa drug African 
American cohorts show large, significant reductions in cognitive disability and poverty risk 
as adults, but no evidence of improvements in schooling or employment. We show that this 
is despite their having experienced larger absolute reductions in infant pneumonia upon the 
arrival of sulfa drugs
2. We reconcile these findings by positing that blacks faced more limited 
opportunities and incentives to translate their improved physical and mental endowments 
into human capital in the pre-Civil Rights Era. Put differently while blacks experienced 
improvements in endowments that translated to a lower risk of poverty later in life, this did 
not occur through investments in formal schooling or training, presumably because of low 
returns to such investments in an era when blacks faced poor schools and low wage returns 
                                                 
2 As we discuss later, this evidence contrasts with previous work which suggests that blacks may have 
had more limited access to sulfa drugs S. Jayachandran, A. Lleras-Muney and K. V. Smith (2010), 
'Modern Medicine and the 20th-Century Decline in Mortality: Evidence on the Impact of Sulfa 
Drugs', American Economic Journal: Applied Economics 2(2): 118-146. in line with racial 
segregation in hospital access D. Almond, K. Chay and M. Greenstone (2006), 'Civil Rights, the War 
on Poverty, and Black-White Convergence in Infant Mortality in the Rural South and Mississippi', 
MIT Department of Economics.. We suggest that the widespread outpatient use of sulfa drugs 
(estimated at 70%; see section 2), which were also relatively inexpensive, limits the importance of 
barriers to hospital care.  
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to education.  This underlines the importance of political and social institutions in mediating 
long run impacts of early life shocks. It contributes to debates regarding the origins of 
contemporary race gaps in test-scores and educational attainment (Chay et al., 2009), 
underlining the complementarity of early life health with human capital investments, a theme 
that is familiar from (Cunha and Heckman, 2007) but that relies upon what is still a limited 
evidence base. 
Our research relates more generally to two independently flowing streams of the 
literature. One is the debate regarding the causes of underdevelopment, which remains 
unsettled on the question of how much health contributes to productivity (Gallup and Sachs, 
2001; Acemoglu and Johnson, 2007). The other concerns the origins of socioeconomic 
inequality in early childhood. Large tracts of this literature focus upon the influence of 
parental resources and attitudes on investments in children (Black et al., 2007; Cunha and 
Heckman, 2009). This paper contributes to an emerging strand that focuses upon the 
importance of early life health (Currie, 2009; Almond and Currie, 2011). Evidence pertaining 
to the benefits of investments in child health is clearly of huge relevance in today’s poor 
countries, but there is a scarcity of consistent causal evidence (Glewwe and Miguel, 2008).  
Some previous studies examine persistent impacts of infectious disease, for example, 
(Costa, 2005; Bozzoli et al., 2009; Case and Paxson, 2010). Cleaner identification is afforded 
in studies that exploit natural or policy experiments. In a seminal study (Almond, 2006) 
identifies long run effects of in utero exposure to influenza pandemics; also see (Kelly, 2009). 
We contribute to recent work that investigates the impact of public interventions, the policy 
implications of which are clearer. Earlier studies have focused upon childhood exposure to 
malaria eradication (Bleakley, 2010; Cutler et al., 2010; Lucas, 2010; Venkataramani, 2010) or 
deworming (Baird et al., 2011). 
We advance the literature in several ways. First, we provide the first estimates of the 
long-run sequelae of pneumonia, the public health importance of which was set out earlier.
3 
Second, we use a richer set of controls than many of the earlier studies. Third, we look at 
                                                 
3 Using longitudinal data for the 1950-1980 birth cohorts in twelve OECD-member countries, 
Bozzoli et al. identify a significant impact of postneonatal mortality rate on adult height. They show 
that this is largely driven by pneumonia. In a longitudinal study of British men, Barker (1992) found 
that bronchitis, pneumonia, and whooping cough before age 5 are associated with reduced mean 
forced expiratory volume in one second (FEV1) at ages 59 to 70. We use quasi-experimental data and 
extend these findings to consider other outcomes, importantly, including socioeconomic outcomes.  
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changes in the disease environment of a scale that may plausibly be brought about by current 
day interventions in developing countries. In contrast, the pandemic conditions and (near)-
total eradication campaigns examined in previous studies are dramatic events.
4 Fourth, our 
use of sulfa drugs as a source of identifying variation allows us to provide the first estimates 
of the long-run benefits of medical therapeutics. Our findings may therefore motivate 
investment in medical research and changes in extant patent laws and marketing structures 
to help promote the distribution of pharmaceuticals such as antibiotics at affordable prices 
in the developing world (this discussion is developed in the Conclusion).  
The rest of the paper is laid out as follows. Section 2 discusses the sulfa drug 
revolution and its effects on pneumonia mortality and morbidity in the United States. 
Section 3 sets out our research strategy, and Section 4 describes the data. Section 5 presents 
the results and Section 6 discusses policy implications and concludes. 
2. Pneumonia and the Sulfa Drug Revolution 
We first describe the prevalence and distribution of pneumonia in the 1930s, 
underlining its contribution to overall mortality rates and its particularly high incidence in 
infancy. We then provide evidence of the sharp drop in pneumonia mortality and 
corresponding declines in morbidity that flowed from the introduction of sulfa drugs in 
1937. We further show that this stimulated convergence in pneumonia rates across the US 
states. 
Pneumonia is an inflammatory disease of the lungs largely caused by infectious 
agents such as bacteria and viruses. The symptoms of pneumonia include cough, shortness 
of breath, chest pain, and fever. There are several ways in which pneumonia may impact 
long-run health and socioeconomic outcomes. First, the inflammation associated with 
pneumonia requires energy, and infant exposure to the disease may divert nutrients from 
being used towards cognitive and physical development, which can lead to reduced cognition 
                                                 
4 Influenza mortality increased four-fold during the flu epidemics analyzed while the sulfa-induced 
decline in pneumonia mortality rates was 17% (all ages: Jayachandran et al. 2010) to 30% (infants- 
our estimates). So, epidemic infection rates are some orders of magnitude larger than endemic rates. 
It may be that there is some threshold below which population level impacts are not discernible, 
making it difficult to generalize the results of pandemic infection studies to the case of more subtle 
interventions in the disease environment such as associated with health campaigns, clean water 
programs or the distribution of medicines.  
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and worse health later in life
5. The consequences of this metabolic cost are likely decreasing 
in age: for example, infants expend some 87% of their metabolic energy in brain 
development (compared to 25% in adults), leaving them more vulnerable to scarring (Eppig 
et al., 2010). Second, inflammation is associated with a loss of appetite, which leads to 
reduced nutritional intake during a time when it is needed most. Third, lung architecture 
develops in utero and in the first three years of life (Shaheen, 1997): it seems plausible that 
early lung damage has persistent effects on more general development. It may also reduce 
the capacity to play, learn and work, all of which have socioeconomic consequences. Finally, 
any direct physiological damage is likely to be reinforced by reduced human capital 
investments both because of dynamic complementarities and because the reward to these 
investments is increasing in life expectancy. 
In the 1930s, pneumonia accounted for 10% of all-age deaths in the United States 
and about 44% of neonatal deaths.
6 The underlying incidence of pneumonia was high as 
well, though this is more difficult to pin down because of patchy and unreliable data. 
Estimates from the US National Health Survey of 1934-1936 show a nationwide morbidity 
rate of 3 cases per 100 infants, with rates twice as high among the poor and those living in 
crowded conditions (Britten, 1942). However, it is likely that this represents a significant (at 
least two-fold) underestimate of the true pneumonia burden (Klugman and Feldman, 2009). 
Indeed, pneumonia in the 1930s United States may have had a similar incidence and 
prevalence as it does in today’s developing countries, where it is estimated that there are 
between 15 and 28 pneumonia cases per 100 children under the age of 4 each year (Rudan et 
al., 2004; Lopez et al., 2006).  
Pneumonia, both then and now, preferentially attacks very young children and the 
elderly. Using data from the 1934-1936 National Health Survey, Britten (1942) illustrates that 
pneumonia morbidity was twice as high for infants as it was for 1-4 year olds, and nearly 10 
times as high as for 10-15 year olds (Figure 1). Pneumonia was more prevalent in the US 
                                                 
5 On the other hand, epidemiologists have suggested that brain sparing strategies operate in babies 
whereby neural development is prioritised over other aspects of growth in conditions of resource 
scarcity (Scherjon et al. 1996, Almond and Currie 2011), so the extent to which infection has 
cognitive impacts is an empirical question. 
6 Young children tend to be more vulnerable to contracting and sustaining infections such as 
pneumonia because their immune systems are underdeveloped. The all cause neonatal mortality rate 
per 1000 births in 1930 was 3.6 and mortality from pneumonia was 1.6. By 1940 these rates had 
dropped to 2.4 and 1.1 respectively.  
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South and some parts of the West (Figure 2). This is consistent with the known risk factors 
for (bacterial) pneumonia (poverty, overcrowding, and poor nutrition) being relatively 
pressing issues in the poorer American South in the 1930s (Klugman and Feldman, 2009; 
van der Poll and Opal, 2009). As we discuss in the next section, our research strategy 
exploits this age and geographic variation.  
Prior to the arrival of sulfa drugs, pneumonia was primarily treated with supportive 
care. In the early 1930s, a small but growing number of clinicians began to use intravenous 
serum therapy to combat bacterial pneumonia, which was often more severe and conferred a 
higher risk of death than its viral counterpart (Lesch, 2007).
7 Serum therapy was an 
expensive and time-intensive process restricted to hospitalized patients. There is nevertheless 
some clinical evidence of its effectiveness in reducing pneumonia mortality rates (Finland, 
1960).  
The antibiotic properties of sulfonamides were first noted in 1932 by German 
chemists conducting experiments on textile dyes. Evidence of their anti-microbial potential 
was first published in 1935 and confirmed in clinical trials conducted in the following two 
years (Gibberd, 1937; Long and Bliss, 1937; Kiefer, 2001; Lesch, 2007; Jayachandran et al., 
2010). A December 1936 New York Times article lauded the potential benefits of sulfa and, 
by early 1937, the drugs became widely available in the United States. They were relatively 
inexpensive and heavily promoted, leading to a “sulfa craze” that lasted until the arrival of 
the first penicillins in 1942-44.   
The arrival of sulfa drugs represented a tremendous boon to clinicians treating 
pneumonia. The first sulfa agents, such as Prontosil, were only somewhat effective against 
Streptococcus pneumonaie, the agent responsible for the majority of bacterial pneumonias. 
However, in 1938, sulfapyridine (also known as M&B 693), became available for clinical use. 
Clinical trials conducted soon after sulfapyridine became available showed striking 
reductions (of 50-70%) in pneumonia case fatality rates among inpatients (Evans and 
Gaisford, 1938; Gaisford, 1939; Lesch, 2007). Within months after its introduction, the use 
of sulfapyridine for treating pneumonia became widespread. 
                                                 
7 This involved obtaining antibodies from animals that were infected with a specific microbe. Serum 
refers to the component of animal blood comprised of fluid and antibodies, which has to be 
separated from the cellular component. The serum was injected intravenously into human patients, 
where the antibodies from the animal would bind to the infectious agent and aid the endogenous 
immune response (Lesch, 2007).   
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In addition to the benefits noted in small clinical trials, the arrival of sulfa drugs had 
large impacts on mortality from pneumonia at the population level. Using state and national 
time series data for the United States, Jayachandran, et al (2010) demonstrate structural 
breaks in the time series data for mortality from sulfa treatable diseases around the time the 
drugs first became available. They estimate that sulfa drugs led to a 17% decline in 
pneumonia mortality. The decline was larger, at 32%, amongst infants (see footnote 3). Figure 
3, which plots the trend in national pneumonia mortality rates illustrates these findings 
nicely. Prior to the arrival of sulfa, pneumonia rates held steady which suggests that 
serotherapy had little impact on population level pneumonia mortality rates. The death rate 
began to drop in 1937 (though it still was higher than in the 1930-1935 period) and then fell 
sharply in 1938 and thereafter. This pattern is consistent with the arrival of sulfa drugs better 
suited to combat pneumococcal bacteria in 1938. Continued gains are consistent with 
increasing market penetration and diffusion of information and acceptability of the new 
drug.
8 
Figure 4 examines the state-specific post-sulfa absolute reduction in pneumonia 
mortality as a function of the pre-sulfa rate in the birth state. This shows convergence in 
pneumonia mortality across states after 1937, confirming our prior that states with a greater 
initial burden of disease from pneumonia gained more from the arrival of sulfa drugs.  
Because our goal is to examine the long-run impacts of pneumonia exposure, it is 
important to explicitly examine the effects of sulfa drugs on pneumonia morbidity, as well as 
mortality, at the population level. If the advent of sulfa drugs only saved the lives of those 
with severe cases of pneumonia, our long-run impact estimates may simply reflect selection 
or composition effects. If sulfa therapy additionally reduced morbidity amongst survivors 
then our long run estimates will tend to capture scarring net of any selection.  
There is, in fact, compelling evidence that sulfa drugs led to reductions in the severity 
of pneumonia episodes. With respect to hospitalized patients, a number of clinical trials on 
infants and children from the era cite rapid improvements in fever, mental status and other 
physical examination findings, illustrating that the average inpatient case of pneumonia was 
                                                 
8 In the next section we explain that the data series plotted in Figures 2 and 3 is for influenza plus 
pneumonia as this is the category for which annual state series are available. The fluctuations in the 
series prior to 1937 are driven by influenza outbreaks (Jayachandran et al., 2010). In the next section 
we provide evidence that the drop in the combined series in 1937 is entirely on account of 
pneumonia, influenza having shown no change, at least not for babies.  
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shorter in duration and followed a less severe course as a result of sulfa chemotherapy 
(Hodes et al., 1939; Smith and Nemir, 1939; Moody and Knouf, 1940; Greengard et al., 
1943). Data on industrial workers illustrate a 20-30% reduction in the number of illness days 
after the arrival of sulfa drugs (Ungerleider et al., 1943). Along the same lines, comparisons 
of US Army experiences between the first and second World Wars suggest that sulfa drugs 
were instrumental in drastically reducing the severity of and infirmity time from pneumonia 
among soldiers. In addition, sulfa drugs were widely available to and utilized by laypersons 
and community physicians soon after their arrival in the US (Lesch, 2007). Thus, it is likely 
that pneumonias treated in the community - roughly 70% of all cases, according to Britten 
(1942) - would be less severe and shorter in duration than in the absence of antibiotic 
therapy and less likely to warrant hospitalization.  
Regarding the incidence of pneumonia, in theory it is possible that antibiotic therapy 
would reduce the probability of contracting pneumonia since those undergoing treatment 
will produce fewer respiratory secretions and so be less contagious. However, the evidence is 
mixed. On the one hand, incidence rates in the sample of industrial workers alluded to above 
did not appear to decline once sulfa-drugs became available (Ungerleider et al., 1943). On 
the other, data from the Boston City Hospital suggest that pneumococcal bacteremia rates 
among hospitalized patients fell drastically after sulfa drugs became available (McGowan et 
al., 1975). Regardless, as measures of pneumonia incidence are sensitive to improvements in 
surveillance and diagnosis, it is difficult to draw firm conclusions from the available data. As 
such, while we can state confidently that sulfa drugs led to noteworthy reductions in the 
length, severity and risk of death from pneumonia, we do not have reliable evidence on 
whether they led to reductions in the probability of contracting the infection altogether. 
However, our research strategy accounts for contagion-related spillovers by virtue of 
estimating population-averaged impacts. 
3. Data 
  Data for the outcome variables were taken from the 1980, 1990, and 2000 5% 
samples of the United States Census. The marginal cohort born around the time sulfa drugs 
first became available was 43, 53, and 63 years old at the time of each of these enumerations, 
respectively. We calculated means for each outcome by birth state, birth year, census year, 
race and gender and used the cell means in the analysis. Assessing impacts at the cell level 
allows us to account for cohort-level general equilibrium effects. To avoid measurement  
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error, we dropped cells in the bottom 1% of the cohort size distribution (i.e., those with less 
than 50 persons), although our results are not sensitive to this.  
The main outcomes we examine are years of schooling, logged household income, 
poverty status, employment status, and work limiting or preventing disability. These 
outcomes are available in all three censuses. In general, we use data from all three census 
waves as this improves the precision of our estimates.  For schooling, we produced estimates 
using only the 1980 census to avoid duplicating the data given that years of schooling seldom 
change after the age of 43 (the age of the marginal sulfa cohort in our sample in 1980). We 
also analyse physical and cognitive disability which are only available in the 2000 census. The 
Data Appendix contains details and definitions and Appendix Table A1 presents descriptive 
statistics.  
Data on all-age disease-specific mortality rates are from the US Vital Statistics and 
were gathered by Anne Case, Adriana Lleras-Muney and Grant Miller and supplemented by 
us. Information on the socioeconomic characteristics of states come from various sources 
(see Data Appendix). For the period of interest, state-level time series data on pneumonia 
mortality are aggregated with influenza mortality so we, like Jayachandran, et al (2010) work 
with this compound variable. Combining mortality rates from these causes may lower 
measurement error, given that surveillance systems may have conflated influenza and 
pneumonia deaths and a large portion of influenza deaths were caused by secondary bacterial 
pneumonia
9  
4. Research Strategy 
Individuals who contract pneumonia are not a random draw from the population. 
For example, infection rates were higher in the US amongst the poor, rural residents, and 
African-Americans (Britten, 1942). So, even if disease exposure had no causal effects on later 
life attainments, we would likely observe that increased disease exposure in childhood was 
associated with lower socioeconomic status in adulthood. Since the nationwide arrival of 
sulfa drug technology was uncorrelated with individual and state level characteristics, we 
avoid this problem by exploiting the sharp cohort variation in pneumonia exposure (Figure 3) 
                                                 
9 National level vital statistics data for the years 1930 and 1940 which disaggregate influenza and 
pneumonia among infants show that pneumonia accounted for the bulk of the joint pneumonia-
influenza category and that declines in pneumonia dominated the decline in the combined indicator. 
Amongst neonates, pneumonia declined from 1.6 to 1.1 per 1000 live births while influenza held 
steady at 0.2. This is consistent with influenza, which is viral, being unresponsive to sulfa.  
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along with the cross-state convergence in pneumonia burdens that it induced (Figure 4). Our 
baseline specification is: 
 
Yrstc = α + β*postt*base_pneumonias + δs + ζt + γr + μc + θrs + ηrt + λrc + erstc    
       
where Yrstc denotes an outcome recorded in adulthood for individuals of race (r), birth state 
(s) and birth year (t) observed in census year (c). The outcomes, listed earlier, are indicators 
either of human capital or of the returns to human capital.  We define postt = 1 for cohorts 
born in 1937, the year sulfa drugs were introduced and thereafter. The pre-sulfa pneumonia 
mortality rate in the birth state is denoted base_pneumonias and may be thought of as capturing 
treatment intensity. Infectious disease mortality rates are commonly used to proxy disease 
exposure; for a formalization of the rationale for this, see Bozzoli et al. (2008). Our research 
strategy is similar in spirit to that employed by (Acemoglu and Johnson, 2007; Bleakley, 
2007; Lucas, 2010).  
The Greek letters represent race-specific fixed effects for birth state, birth year and 
census year. As we discuss further below, we estimate every model separately by gender and 
some also by race. Standard errors are clustered at the birth state level to account for serial 
correlation in the outcomes (Bertrand et al., 2004). Regressions are weighted by cell size, 
although we note that the estimates are not sensitive to this. We restrict our analysis to the 
time period 1930-1943 in order to reduce the possibility of confounding from other public 
health events or interventions, for example, the influenza epidemic of 1928-9 and the 
increasingly widespread use of penicillin after 1943.  
The estimated equation may be thought of as the reduced form of a system in which 
adult outcomes are allowed to depend upon pneumonia exposure at birth and the latter is 
instrumented with the sharp arrival of sulfa drugs, the impact of which varies across states as 
a function of their pre-sulfa pneumonia burden. The parameter β will capture the full impact 
of sulfa-induced reductions in pneumonia exposure. This will include direct biological 
impacts of pneumonia infections on physiological growth including cognitive development 
in infancy and its impact on incentives to invest in human capital
10.  
                                                 
10 It will in principle also include any indirect impacts flowing, for example, from the increase in 
household resources generated by lower pneumonia morbidity amongst parents of the index cohort.  
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4.1 Unobserved heterogeneity at the birth state and birth year level 
The main threats to inference with the basic differences-in-differences sort of model 
above are unobservables that vary by birth state and birth year and are correlated with both 
pneumonia exposure in infancy and the outcomes. We therefore investigate sensitivity to a 
variety of controls for trends in health and socioeconomic conditions in the birth state.  
Diseases Not Treatable by Sulfa Drugs: A particular concern is that post may pick up 
coincident factors other than sulfa drug availability that led to sudden improvements in 
health. A powerful check against this is to use information on trends in diseases that were 
not treatable with sulfa drugs. The premise is that omitted factors will not have discriminated 
between sulfa-treatable and sulfa-untreatable diseases. We interact post with pre-sulfa birth 
state specific mortality rates from tuberculosis, under-2 diarrhea, malaria, heart disease and 
cancer and include these as controls in our model. In this way we allow the outcomes to 
evolve as discontinuous functions of these five other diseases. Inclusion of the 
communicable diseases (tuberculosis, diarrhea, malaria) helps control for state specific 
changes in sanitation, public health programs, housing (etc) that may have coincided with the 
arrival of sulfa. For example, there were significant declines in malaria in this period (Barreca 
2010). Controlling for malaria is likely to be particularly important to isolating the impact of 
pneumonia given that it, too, enjoyed a higher prevalence in the South and given the 
established potential of malaria to impact long-run outcomes (Barreca, 2010; Bleakley, 2010; 
Venkataramani, 2010). Including diarrhea, a disease of childhood, helps control for 
unobservables specific to the young. Inclusion of non-communicable diseases is expected to 
control for factors such as health care quality and access. 
Diseases Treatable by Sulfa Drugs:  Sulfa drugs led to marked declines in conditions 
other than pneumonia, most notably scarlet fever, erysipelas, meningitis and puerperal sepsis 
(Jayachandran et al. 2010). Thus, the coefficient on postt*base_pneumonias may have loaded on 
to it the effects of reductions in (omitted) sulfa-treatable diseases. However, scarlet fever, 
erysipelas and meningitis accounted for a negligible fraction of infant mortality. In 1930, the 
number of infant deaths in 1000 live births from these diseases was 0.1, 0.3 and 0.2 
compared with 8.9 from pneumonia.  
                                                                                                                                                 
Since pneumonia infections amongst adults of child-bearing age were relatively scarce (Figure 1), we 
expect the indirect effects to be small.  
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In contrast, puerperal sepsis accounted for 40% of maternal deaths in 1930 and 
maternal mortality was high, at 7.03 deaths per 1000 births. Furthermore, maternal mortality 
rates fell sharply in 1937 (Thomasson and Treber, 2008; Jayachandran et al., 2010). To 
account for this we control for maternal mortality rates, allowing their impact to break in 
1937 (i.e. we include postt*base_maternal mortalitys). This is crucial because maternal mortality 
declines may influence long-run outcomes for the cohorts in our sample. At the population 
level, parents may perceive greater returns to early life investments in girls when maternal 
mortality rates are lower, potentially leading to improvements in long-run outcomes for 
women vis-a-vis men (Jayachandran and Lleras-Muney, 2009). At the individual level, there 
are clearly consequences for boys and girls from one’s own mother dying. There may be 
additional impacts flowing from changes in family size that arise because of changes in the 
probability of infertility, a potential complication of post-partum fever
11.  
Time-Varying State Characteristics: To further address pre-existing trends, we control for 
birth state-birth year varying socioeconomic variables including logged state income per 
capita, the numbers of schools, hospitals and physicians per capita, and state per capita 
public health spending
12. The inclusion of income per capita in the state of birth is pertinent 
given changes in economic fortunes during the Depression Era, even if these have been 
shown to have had little, if any, impact on long-run health and economic outcomes (Cutler 
et al., 2007). To allow for any remaining converging/diverging trends at the birth state level, 
we investigate specifications with birth state specific linear (and quadratic) time trends and 
census division*birth year fixed effects. These additional specifications are motivated in part 
by convergence in economic development between the US South (which was particularly 
plagued by pneumonia) and other parts of the country during the 20
th century (Mitchener 
and MacLean, 1999). 
Including these additional variables may amount to “over-controlling.” For example, 
the increased risk of infections from weakened immune systems as well as competing risks 
from different conditions create population level correlations in disease rates. Thus, 
controlling for additional diseases may capture variation in disease trajectories that are in fact 
driven by the use of sulfa drugs rather than by unobserved confounding factors. Similarly, 
                                                 
11 Any such effects are necessarily indirect because the maternal post-partum infections (puerperal 
sepsis) that were controlled with sulfa drugs were not transmitted to infants. 
12 The estimates are not sensitive to whether we include post multiplied by the pre-intervention level 
of the characteristic (postt*Xs) or we directly include the characteristic (Xst).  
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controlling for state trends is typically quite demanding of the data. We therefore present 
results with and without each set of controls. Robustness checks are, unless otherwise 
specified, presented for the specification with the richest set of controls. The robustness 
checks are detailed in the results section. 
4.2. Age of Exposure 
In an extension of the baseline specification which models birth year exposure, we 
allow for returns to sulfa exposure at other ages. Though far lower, pneumonia mortality 
rates were still considerable for those aged 1-5 (Figure 1).
13 To investigate whether exposure 
to pneumonia at these ages had impacts, we replace post with a vector of birth year dummies 
for every year in the sample and then graph the coefficients on birth yeart*base_pneumonias. 
This specification also provides a useful falsification test: the presence of breaks in the 
coefficients in years other than around 1937 may suggest that the patterns seen in the data 
are due to some process other than the introduction of sulfa drugs. As we discuss later, we 
also exploit the age gradient in the coefficients to estimate a triple difference model, using 
the approximately ten-fold variation in pneumonia infection rates across age groups as an 
additional measure of treatment intensity. 
4.3. Gender and Race Heterogeneity 
Males may benefit more from early life medical interventions because they are 
biologically more vulnerable to infections, as well other aspects of an adverse early childhood 
health environment (Waldron, 1983; Low, 2000; Gluckman and Hanson, 2005). Indeed, 
surveillance data from the mid-1930s show that boys were 27% more likely to contract 
pneumonia in infancy than girls (Britten, 1942). Any biological differences may be 
moderated or reinforced by gender-specificity in the sensitivity of parental investments to 
health endowments. For example, human capital investments induced to complement the 
better health endowments of post-sulfa births may have been weaker for girls because of 
their more limited opportunities for advancement in the labor market (i.e., lower returns to 
investments). Evidence of a pro-male bias in contemporary times in the United States 
(Stanley and Jarell, 1998; Dahl and Moretti, 2008) lends credence to considering a behavioral 
angle in addition to biological factors. 
                                                 
13 In contrast to Almond (2006) and Kelly (2009), we do not expect impacts from fetal exposure 
because mothers of childbearing age experienced very low infection rates (Britten, 1942).  
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Race-specific models are warranted given that pre-sulfa pneumonia mortality for 
African Americans was about twice as high as that for whites, which implies that they had 
more to gain from the introduction of sulfa drugs. This alone would lead us to expect larger 
long-run impacts amongst blacks. On the other hand, there was racial segregation in hospital 
care and hospitals serving the black population were often less well equipped (Almond et al., 
2006). Moreover, differentials in school quality and returns to education between blacks and 
whites were more marked prior to the Civil Rights Act of 1965 (Donohue and Heckman, 
1991). Thus, human capital accumulation may not have responded to improved health 
endowments for blacks vis-à-vis whites for the reason discussed above in the case of women 
versus men – there may have been limited opportunities to capitalize on and lower returns to 
improved physical and mental endowments. 
5. Results 
5.1. Main Results 
Refer  Table 1, where each cell reports estimates of the coefficient on 
postt*base_pneumonias from a separate regression. The rows denote the outcome variables and 
the columns different sets of control variables. We find that exposure to sulfa drugs, and 
thereby, reduced exposure to pneumonia has substantial and statistically significant impacts 
in the expected direction on every outcome for men. These results are remarkably robust to 
successive inclusion of controls for other diseases, state socioeconomic and infrastructure 
characteristics, state specific linear time trends, and census division X birth year fixed effects. 
The specification with all of these controls implies a post-sulfa gain of 0.19 in years of 
schooling associated with shifting the pre-sulfa pneumonia death rate (base_pneumonia) from 
the 75
th to the 25
th percentile of its distribution (i.e., from 1.18 to 0.92 deaths per 1,000).
 The 
same change in base implies a 2.83% increase in family income, a 0.42 percentage point 
decrease in the probability of being below 200% of the federal poverty line, a 0.75 
percentage point increase in the probability of being employed, and a 0.61 percentage point 
decrease in the probability of reporting a disability limiting or preventing work.
14  
The estimated coefficients are of a similar magnitude for women in the specifications 
with birth state and birth year fixed effects and control diseases (columns 1 and 2). However, 
                                                 
14 A one standard deviation change in pre-intervention pneumonia is 0.19. Our estimates suggests that 
this causes the following changes in long run outcomes: a 0.16 s.d. increase in education, a 0.04 
increase in log income, a 0.02 percentage point increase in the chances of being employed and a 0.03 
decrease in the risk of having a work-related disability.  
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they are generally diminished and driven to insignificance by the inclusion of state 
socioeconomic variables and state specific trends.
15 As we discuss below, invoking a third 
difference in age of exposure produces estimates for women that are robust to the richest set 
of controls.  
Figures 5 and 6 plot the coefficients on birth year*base_pneumonia
16 In line with the 
results in Table 1, the sharp sulfa trend breaks are either more muted or non-evident for the 
estimates for women. The coefficients for men show trend breaks consistent with the timing 
of the arrival of sulfa drugs. For almost all of the outcomes, the effect sizes jump and climb 
over the period 1937-1939, consistent with the earliest sulfa drugs being less effective in 
treating pneumonia than sulfapyridine, which was introduced in 1938 and became widely 
used by 1939.
17 There is no evidence of trend breaks in years other than those associated 
with the introduction of sulfa. Furthermore, the coefficients for men prior to 1937 generally 
hover around zero indicating that the returns to sulfa exposure were likely limited to the 
birth year.  
This suggests that the birth year is a “critical period” for investments designed to 
control infectious diseases and in particular pneumonia. As discussed earlier, this ties in with 
(a) pneumonia morbidity and mortality rates being far higher for infants than for older 
children and (b) the developmental changes induced by infectious disease being greater the 
younger the child is at exposure (Barker, 1992; Eppig et al., 2010).  
5.2. Additional Disability Variables 
A potential problem with our self-reported work related disability measure is that it 
may be prone to “justification bias” if the welfare regime encourages individuals to invent or 
exaggerate disability (Autor and Duggan, 2003).
  We investigate additional measures of 
disability that are unrelated to work participation and so may serve as cleaner measures of 
                                                 
15 We do not find any evidence of a relationship between exposure to lower maternal mortality rates 
and long-run outcomes. The coefficient on post*base_MMR tends to take the unexpected sign and is 
generally insignificant in Table 2 for men and women. So either reductions in maternal mortality did 
not change parental investments in a way that led to long-run changes in health and socioeconomic 
status, or the investment effects of maternal mortality declines through the pathways discussed earlier 
offset each other. The coefficients on the vector of sulfa-untreatable diseases similarly tend to be 
insignificant or of the unexpected sign. 
16 These coefficients are from a specification with the controls in column 3 of Table 2. The plots 
look very similar if we include state specific trends in the control vector.  
17 We examined similar coefficient plots from an identical equation for heart disease, a control 
disease, trends in which were not directly influenced by the arrival of sulfa. We find no evidence of a 
trend break in 1937. These ‘difference in difference’ graphs are in Appendix Figures A2 and A3.  
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health. These are indicators for whether individuals reported experiencing difficulties with 
basic physical and cognitive tasks, available only in the 2000 census when the marginal 
cohort is 63. There is some previous evidence that early life infections may accelerate 
cognitive decline in old age, possibly through their effects on cardiovascular health (Costa, 
2005) or adult neurogenesis (Ekdahl et al., 2003) 
The results are in Table 2. Men born after the introduction of sulfa drugs experienced 
a substantial reduction in the risk of cognitive disability. The estimates suggest that a move 
from the 75
th to 25
th percentile of the pre-sulfa baseline pneumonia mortality distribution is 
associated with a 0.66 percentage point decrease in the probability of reporting a cognitive 
disability amongst post-sulfa cohorts. The cognitive disability coefficients, while driven to 
insignificance upon inclusion of state specific trends, are not diminished in magnitude. The 
estimates for physical disabilities are sensitive to specification and not statistically significant. 
Women show no significant change in either disability risk post-sulfa.  
The positive and significant findings for men across all outcomes versus the lack of 
such findings for women is consistent with men being biologically more vulnerable to early 
childhood health shocks than women. It is also consistent with reduced investment in 
women as a result of taste-based discrimination or statistical discrimination on the basis of 
low (expected) returns to human capital. We will return to this point below, and attempt to 
ascertain the relative importance of each explanation.  
5.3. Race Specific Effects 
Refer Tables 3-4. The results for white men and women mirror those for all men and 
all women, but the coefficients for African Americans are generally smaller and less 
imprecisely estimated. Poverty and cognitive disabilities are two important exceptions as 
black men show twice as large a sulfa-related reduction in both of these variables as white 
men, possibly because the treatment effect is larger in the region of the distribution where 
their baseline outcomes lie. Of note, while for both variables the estimates tend to lose 
significance as additional controls are added, they maintain their magnitudes and are 
consistently larger than the corresponding estimates for whites. To address whether the 
weaker estimates for blacks for the other outcomes are driven by measurement error in 




18 While using the race-specific measure lowers the standard errors on the 
coefficients for blacks, there is still no evidence that their education, employment, income or 
work-related disability improved post-sulfa (results available upon request).  
The race difference in our findings may arise for one of two reasons: (a) Either 
African Americans did not benefit as much from the arrival of sulfa in the 1930s or (b) they 
did but were unable to translate improved health and cognitive endowments into long run 
socioeconomic gains The first hypothesis is put forward in Jayachandran et al. (2010) who 
hypothesize that blacks had reduced access to hospitals and health care technology, thereby 
having reduced access to new therapeutics. However, the trends displayed in Figure 7 suggest 
a larger absolute decline in influenza and pneumonia mortality after 1937 for blacks than for 
whites. We confirm this in regressions which allow us to test for the statistical significance of 
this difference. We find that the trend break in pneumonia mortality and post-sulfa 
convergence across states are both significantly larger for blacks.
19 It would seem that the 
reason this was feasible despite barriers to access to new treatments and segregation in 
hospital care is that sulfa drugs were initially available without prescription and widely used 
in the outpatient setting (section 2 above). Moreover, the cost of a course of treatment with 
this life-saving drug was relatively low, making it less likely that the relatively poor black 
population faced financial barriers to access (Lesch, 2007).
20,21  
                                                 
18 The problem is that almost all states had much larger white than black populations, so the overall 
state mortality rate is a relatively noisy measure of black mortality. A solution is to use separate 
mortality rates for whites and non-whites within each state. However where the non-white 
population is very small, this will introduce measurement error again. To limit this problem, we 
followed Jayachandran, et al (2010) and used their data for states with greater than 10% black 
populations; further limiting the sample to those states with non-white populations greater than 
100,000 individuals. 
19 Using the sample window 1930-43, we regressed the pneumonia mortality rate (in levels, not logs) 
on post*year, controlling for the main effects of post and year and for state dummies. For this exercise 
we used the race-specific state-level mortality rates. The coefficient on post*year indicates a significant 
trend break in 1937 for both races, the coefficients being -0.14 (s.e. 0.016) for blacks and -0.08 (s.e. 
0.010) for whites. To assess post-sulfa convergence in pneumonia across the states we regressed the 
pneumonia mortality rate on post*base, defined as in equation (1). The coefficient on post*base is -0.56 
(s.e. 0.111) for blacks and -0.27 (s.e. 0.185) for whites.  
20 Jayachandran et al. (2010) analyze proportional changes in pneumonia mortality (relative to 
tuberculosis) for which there appears to be no significant race difference in the post-sulfa drop in 
mortality. This is clear in their Figure 6b and we confirm with simple regressions of log mortality by 
race that the trend break in logs is similar.  
21 Our showing that pneumonia amongst African-Americans did respond to sulfa treatment not only 
puts aside hypothesis (a) concerning access to the drugs but also the idea that there are race  
 
19
We posit that our findings are more consistent with the second explanation. The 
larger impacts on cognitive disability and poverty suggest that blacks did benefit from the 
sulfa drug revolution in terms of formation of mental and physical endowments.  However, 
the fact that these cohorts still derived no additional benefit in terms of schooling and 
employment later in adulthood is consistent with the fact that blacks had limited access to 
good schools, good jobs, and faced lower rates of return to human capital in the labor 
market in the pre-Civil Rights Era. Thus the discordance between the poverty and cognition 
outcomes and the other outcomes perhaps stems from the failure of investments in human 
capital to respond to improved endowments due to low rates of return.  
The results for blacks perhaps inform the differential results by gender. However, if 
we pursue the interpretation of the cognitive disability and poverty impacts for blacks as 
implicit evidence of sulfa-drug induced improvements in endowments, the failure to find 
such effects for women, who may have faced similar institutional barriers to human capital 
investment, suggests that the biological sensitivity explanation may dominate the 
investment/institutions explanation for this population. 
5.4. Additional Robustness Checks 
Thus far, we have shown that our core findings are robust to the inclusion of a 
variety of birth state*birth year disease environment and macroeconomic controls, as well as 
flexible birth region trends and linear birth state-specific trends. We have also provided 
evidence in the form of flexible birth cohort specific coefficient plots that long run benefits 
of reduced pneumonia exposure led by the sulfa revolution are first visible for the cohort of 
1937 and are increasing for cohorts born just after, consistent with the established timing of 
the introduction of sulfa drugs and the later development and adoption of sulfa varieties that 
were more potent in treating pneumonia. The evidence is also consistent with the 
epidemiology of pneumonia, which targets infants far more ruthlessly than somewhat older 
children.  
In this section, we consider a number of additional robustness/falsification checks. 
Two relate to the flexible coefficient plots in Figures 5 and 6. In the first, we re-estimate the 
model with a placebo intervention, defining post as 1934 rather than as 1937 onwards. We 
now find no evidence of any long run gains (Table A2). In the second, we further formalize 
                                                                                                                                                 




the intuition behind the coefficient plots. As discussed, infection rates and days of disability 
suffered by pneumonia patients in the pre-sulfa era (1934-36) peaked at birth and reached a 
minimum in the age group 10-24. The difference was a factor of eight to ten (Collins 1931, 
Britten 1942; Figure 1 below). Consequently we expect limited if any long run benefits of 
sulfa to be evident for individuals who were first exposed at, say, age 15 compared with 
individuals exposed at birth.  
We use this insight to estimate a triple difference specification. For this we extended 
the sample back to birth cohorts 1915 and onwards. We now define treated as 1 for 
individuals who were exposed to sulfa at birth (ie born in or after 1937) and as 0 for 
individual who had their first exposure to sulfa at age 10-15. Post is now equal to 1 for 
treated individuals born on or after 1937 and untreated individuals who turned 15 on or after 
1937.  Appendix Figure 1 provides a visual description of how the treatment and control 
groups are set up. The regressor of interest is now post*treated*base_pneumonia and we 
naturally include the underlying two-way interactions and main effects.  
The results are in Table 5, using the richest set of controls, corresponding to column 
5 in Table 1. For men, the estimates are remarkably similar in magnitude and significance to 
those in Table 1.
22 Interestingly, the results for women now show large positive estimates for 
schooling, family income and employment, all of which are statistically significant. Sulfa-
induced gains in schooling and income are smaller for women than for men but their 
employment gains are twice as large.
23 We also now find a significant improvement in work 
disability for black men, which ties in with our finding of improvements for this group in 
other indicators of disability.  
An additional source of bias may come from selective migration. Since the US census 
records the state of birth, we are confident that we are correctly matching individual (or 
                                                 
22 This not only once again reinforces the robustness of the estimates for men but it also tells us that 
the triple difference model works sensibly. 
23 Why are the estimates for women more robust to controls for trended unobservables with a triple 
difference than they were with the double difference? It may be that for women we need a longer 
difference to detect impacts. This is what treated at age 0 versus at age 10-15 adds. This may be either 
because the sulfa effects for women are smaller and so just harder to detect, or because outcomes for 
women had a stronger underlying trend and this makes it harder to detect a discontinuity using 
immediately neighboring cohorts. Overall, the evidence for women is somewhat ambiguous but what 
is clear from studying the double and triple difference estimates is that the coefficients for women 
are (a) smaller for schooling, income and disability and (b) less robust to controls.  
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cohort) outcomes to pneumonia mortality rates faced during infancy
24. However, we cannot 
be sure that the state of birth is truly exogenous. That is, parents may have migrated in 
response to sulfa, thereby selecting the birth state of their children.
25 This will introduce 
endogeneity of the base_pneumonia variable in our regressions, to the extent that migrants are 
selected on unobservable parental attributes. We therefore test for this possibility using 
information on 20-40 year olds in the 1930 and 1940 census files.
26 We regressed log 
population on post*base_pneumonia, and state and year fixed effects (Table A3). This shows the 
expected positive effect of sulfa drugs on population – that is, people of child-bearing age 
who were likely to become parents preferentially moved to states that saw larger reductions 
in pneumonia and other sulfa treatable diseases. However, this effect is completely dissipated 
upon controlling for baseline diarrheal mortality and/or state income per capita (which our 
main models control for), suggesting that disease environment driven migration is not 
driving our main results. 
We also test the sensitivity of our core findings to meaningful changes in the 
estimation sample. First, as in Jayachandran et al. (2010) we re-estimate the equations 
removing the 1935 and 1936 birth cohorts as there was a minor influenza epidemic during 
these years. The point estimates are larger and the qualitative conclusions remain similar 
(Table A4). We experimented with narrowing the window length and, in particular, dropping 
cohorts born after 1941, which is when the US joined the Second World War. The standard 
errors rise but the coefficients are in general fairly robust (results available upon request). To 
check whether the results are driven by the convergence between the South and the rest of 
the country for reasons other than the arrival of sulfa drugs, we re-estimated the equations 
                                                 
24 Regardless, we estimated models that control for the current state of residence in addition to the 
birth state (as in Case and Paxson 2009), and where we only focus on those who moved to states 
other than their birth state. In neither case were there substantive changes to our results (available on 
request). These checks indicate that the impacts we identify are not driven by post-birth migration in 
the direction of better opportunities. 
25 Montalvo and Reynal-Querol (2007) analyse the reverse process i.e. how levels of infectious disease 
respond to migration patterns. The possibility that migration may respond to the infectious disease 
environment has been discussed by Mesnard and Seabright (2009) but we are not aware of many 
tests of this. We are grateful to Alice Mesnard for alerting us to this. 
26  We constructed a state level data set with the number of 20-40 year olds in each state in the years 
1930, 1935 and 1940 (the 1940 census asks individuals to report their state of residence five years 
before enumeration, hence the 1935 data point). Selecting age 20-40 is appropriate because we are 
interested in endogeneity of the birth state of our cohorts born in the 1930s. As birth and death 
create changes in population that are concentrated at the two ends of the age distribution, looking at 
changes in the population aged 20-40 is likely to isolate migration.  
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excluding the South. While the coefficients on schooling and work disability (human capital) 
are smaller, the coefficients for income, poverty and employment (returns to human capital) 
are very similar although less precisely determined (Table A5). We also conducted 
specification checks relating to our use of the census data (results available upon request). 
There is some concern in the literature that the 2000 census microdata sample used in this 
paper may be subject to inaccuracies in age reporting (Alexander et al., 2010). While this 
problem primarily pertains to those over the age of 65, all of whom were born at least two 
years prior to the start of the sulfa era, we still assessed whether our results remained the 
same if the 2000 census was excluded. The substantive results are unchanged.  All in all, the 
rich set of controls and the array of robustness checks allay the concern that our estimates 
are driven by unobserved convergence processes, reinforcing our attribution of the estimates 
to causal effects of pneumonia exposure. 
5.6. Participation, Selection, and Size of Effects   
Our estimates are likely to under-state the impact of birth year exposure to sulfa drug 
driven reductions in pneumonia morbidity and mortality for the following reasons. First, the 
estimates describe cohort averages. However, not everyone was afflicted by pneumonia and, 
among those who were, not everyone was treated by sulfa drugs. Thus, to at least 
approximate intent-to-treat estimates among those who had the disease, we would have to 
divide our estimates by the fraction of infants with pneumonia. As discussed in section 2, 
there are no consistent data on historical infection rates. If we take a case rate of 15 per 100 
child-years to approximate the situation in today’s developing countries, our results for males 
indicate that, moving from a state at the 75
th percentile of the pre-intervention pneumonia 
mortality rate to a state at the 25
th percentile was associated with the following post-sulfa 
improvements for individuals who actually had pneumonia (refer column 5 of Table 1): an 
increase in schooling of 1.27 years, a 18.87% increase in family income, a 2.8% point decline 
in the probability that family income falls below 200% of the poverty line, a 5% point 
increase in the probability of employment, and a 4.07% point decrease in the probability of 
reporting a work preventing disability. These calculations ignore within-cohort spillover 
effects from those afflicted by pneumonia to those that were not. The estimates are large but 
plausible since pneumonia was a long, trying illness. Pneumonia led to an average of 39 days 
of disability per patient in the year just before sulfa arrived (Britten, 1942). Also these  
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estimates are in the same ballpark as recent estimates of the long-run impact of malaria 
eradication or de-worming in developing countries.
27  
Furthermore, conditional upon infection, access to and use of sulfa drugs to treat 
pneumonia may not have been universal, at least in the early years.. This suggests that our 
estimate likely lies below the true average treatment effect on the treated, which is difficult to 
calculate given that there are no available data on the fraction of individuals plagued by 
pneumonia who received sulfa therapy.  
Finally, mortality selection will tend to bias our estimates downwards since frail 
children were probably more likely to succumb to pneumonia than their healthier 
counterparts  (Bozzoli et al., 2009). With the advent of sulfa drugs, more of these children 
would survive past childhood and these innately less healthy individuals are likely to be less 
productive and healthy as adults. Mortality also has another sort of implication that typically 
goes unrecognized. Consider a child, j, born in or after 1937 who is a marginal survivor on 
account of sulfa drugs. For a given health endowment, parents may lower their health 
investment in the next child in that family, j+1,  (born, let us say, in 1939). In other words, 
we will under-estimate sulfa-induced gains to the extent that post-sulfa cohorts have more 
surviving siblings and there is resource competition between siblings. We expect any 
mortality-related bias to be small since pre-intervention death rates amongst infants were 
around 1% (Britten, 1942; Councell, 1963).  
6. Conclusions 
This study delivers the first estimates of the long-run returns to investment in 
medical innovation (of antibiotics) and the first causal evidence of long-term scarring effects 
of early life exposure to pneumonia on indicators of later life health and socioeconomic 
status. Our results suggest that exogenously delivered early life health improvements created 
some tendency towards convergence in socioeconomic status across states and within the 
most effectively treated group (white men) forty to sixty years later. However they generated 
                                                 
27 Malaria eradication is estimated to have led to a 15-27% increase in wage income (Bleakley, 2010) 
and about a 3 year increase in schooling (Lucas, 2010). De-worming in primary schools is estimated 
to have generated 2-3 additional years of schooling and a 21-29% increase in income (Baird et al., 
2011). The four-fold increase in infection (via mothers) during the 1918 influenza epidemic led to 0.25 
years less education and 6% lower income (Almond, 2006). We present estimates of the change in 
long run outcomes for post-sulfa cohorts by simulating the effects of a change in pre-intervention 
pneumonia from the 75th to the 25th percentile of its distribution (which is a 0.26% point change). 
The actual pre-post 1937 drop in pneumonia was, as it happens, similar, at 30%: pneumonia 
mortality fell from 1.1 to 0.79 per 1000 between 1936 and 1938.    
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a more limited narrowing of socioeconomic inequalities across gender and race groups. 
Women exhibit socioeconomic gains in a number of specifications but their education and 
income gains are smaller, consistent with girls being less likely to contract infections in 
infancy and more robust to fighting them off if they do. In contrast, African-Americans were 
more likely to contract infections including pneumonia and they gained more from the 
arrival of the new antibacterials. However they appear to have faced institutional constraints 
in translating improved early life health endowments into educational capital and 
employment.  
Our results are important for developing countries where acute respiratory infections 
are the leading cause of early childhood mortality. The evidence base from developing 
countries on medical interventions targeting pneumonia in children is beginning to grow. 
For example, a recent community-based intervention in India that involved treatment of 
pneumonia in children aged 0-4 years with co-trimoxazole showed a case-fatality rate of 
0.8% in the treatment area compared with 13.5% in the control area. The cost of co-
trimoxazole was US $0.025 per child per year or $2.64 per child saved (Bang et al., 1999). In 
addition, large scale roll-outs of pneumococcal vaccines have shown to be highly efficacious 
in reducing pneumonia incidence and mortality in developed and developing countries alike 
(Cutts et al., 2005).  
Although we now have the technology to prevent and treat pneumonia, only 20% of 
children with pneumonia in developing countries receive the necessary antibiotics (WHO 
2010).
28 The Advance Market Commitment (AMC) and the Health Impact Fund (HIF) are 
recent initiatives directed at garnering commitment of international resources to finance 
preventative and therapeutic innovations and also their large scale distribution in poor 
countries.
29 The first AMC pilot, agreed in 2007, is the pneumococcal vaccine. This is now 
affordable for children in a number of developing countries and it is estimated that it can 
                                                 
28 As priced, antibiotics are largely unaffordable to the poor in developing countries. In part this 
probably reflects institutional failures that mark the provision of health-related and other public 
services. In addition there appears to be a perception that antibiotics are inappropriately used in 
developing countries, and this contributes to vaccines being seen as a more promising alternative. 
29 Collective action to combat infectious diseases is merited by the presence of infection externalities. 
In addition to the ethical case for global action (Pogge 2004, 2009) is the public goods nature of 
R&D advances related to treating infectious disease.    
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prevent more than seven million childhood deaths by 2030.
30 The sustainability of these 
initiatives and in particular the HIF depends upon measurement of health impact 
(Grootendorst, 2009). Our work makes a unique contribution in this context. The standard 
approach is to look for immediate reductions in morbidity and mortality at the patient level, 
often summarized in quality or disability adjusted life years. We show that the benefits of 
treating pneumonia in childhood are, for a given cost, much larger than the standard 
approach would suggest. This is because the standard approach ignores (a) long run and (b) 
socio-economic benefits for survivors and (c) the externalities that flow from lowering the 
duration and intensity of illness.  Accounting for dynamic gains in the health and socio-
economic domain at the population level (so accounting for externalities) helps construct an 
efficiency case for investment that enhances extant ethical and equity-driven considerations 
motivating new global health interventions that target young children.
31 
Our analysis of gender and race differentials in treatment effects suggests that the 
translation of childhood health gains into later life education and productivity may be a 
function of social and political constraints embodied in local or national institutions. This 
provides a compelling illustration of the interaction of childhood health endowments with 
environmentally determined incentives for parents to invest in human capital. Further work 
is merited in two directions. First, in enriching the set of outcomes examined, to include 
cognitive test scores and further indicators of health status. Second, to provide clearer 
insight into the manner in which biological pathways interact with parental investments and 
socio-political institutions.   
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Figure 1: The Age Distribution of Pneumonia in the 1930s  
 
Source: Britten (1942). 
 
Figure 2 – Geographic Distribution of Pneumonia Mortality Rates, 1930-1936 
 
Source: Map drawn by the authors using the all-age influenza and pneumonia mortality rate 
from the US Vital Statistics. 
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Figure 5a. All Men: Birth-Year Specific Coefficients on Pre-Intervention Pneumonia Mortality Rates  
Work Limiting Disability          Schooling   
            
 
Family Income                                                          Poverty 





Notes: Each point reflects the estimate on the interaction between the marked birth year and the pre-intervention 
(base) level of the pneumonia mortality rate in the birth-state. This is conditional upon birth state and birth year fixed 
effects and the full set of controls for mortality from other diseases and state macroeconomic and infrastructure 
variables (i.e., the control vector in Column 3 of Table 1). The vertical line denotes the year sulfa drugs became available 
in the United States. Agents more efficacious against pneumonia became available in 1938. Plots including a control 
disease are in Appendix Figures A2, A3. These plots show how the sharp fall in pneumonia in 1937 seen in Figure 3 is 
mirrored in socioeconomic and health indicators in 1980-2000. 
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Figure 5b. All Women: Birth-Year Specific Coefficients on Pre-Intervention Pneumonia Mortality Rates  
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Notes: See notes to Figure 5a 
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Source: US Vital Statistics   34
Table 1:  Main Results by Gender 
 
All Men  (1)  (2)  (3) (4) (5) 
  
Work Limiting Disability (%)  -2.918*** -2.596*** -1.801*** -1.000  -2.332***
(N = 3336, mean = 15.86)  (0.599)  (0.497)  (0.590)  (0.997)  (0.864) 
  
Schooling (Years)  0.399*** 0.328*** 0.350***  0.518***  0.732*** 
(N = 1130, mean = 12.17)  (0.105)  (0.0829)  (0.108)  (0.0823)  (0.150) 
  
Family Income (log)  0.0387***  0.0371***  0.0517*** 0.0805*** 0.109*** 
(N = 3336, mean = 10.57 )  (0.0138)  (0.0124)  (0.0166)  (0.0186)  (0.0191) 
  
Poverty (%)  -2.72*** -2.71*** -1.57** -2.77** -1.61* 
(N = 3336, mean = 24.4)  (0.540)  (0.511)  (0.768)  (1.12)  (0.884) 
  
Employment (%)  1.565*** 1.544*** 2.539***  2.721** 2.897* 
(N = 3336, mean = 67.59)  (0.573)  (0.447)  (0.507)  (1.078)  (1.606) 
  
All Women    
  
Work Limiting Disability (%)  -2.487*** -2.016*** -0.366  1.439*  1.768** 
(N = 3378, mean = 15.21)  (0.691)  (0.572)  (0.660)  (0.772)  (0.798) 
  
Schooling (Years)  0.410*** 0.396*** 0.197*  -0.0180  -0.0253 
(N=1137, mean = 11.95)  (0.0848)  (0.0800)  (0.108)  (0.156)  (0.182) 
  
Family Income (log)  0.0545*** 0.0506*** 0.0325** -0.00507  0.0364 
(N = 3378, mean = 10.44)  (0.0147)  (0.0125)  (0.0135)  (0.0197)  (0.0233) 
  
Poverty (%)  -3.86*** -3.28*** -1.88** -0.724  -1.70 
(N = 3378, mean = 29.8)  (0.746)  (0.623)  (0.897)  (1.24)  (1.39) 
  
Employment (%)  -1.018 -0.825 1.895***  1.022 -0.436 
(N = 3378, mean = 52.13)  (0.651)  (0.583)  (0.646)  (1.112)  (1.387) 
  
Controls    
Birth State, Birth Year FE   Yes   Yes   Yes   Yes   Yes  
Post*BaseRate(Control Diseases)   No   Yes   Yes   Yes   Yes  
Birth State X Birth Year Variables   No   No   Yes   Yes   Yes  
Birth State Linear Trends   No   No   No   Yes   Yes  
Birth Region X Birth Year FE   No   No   No   No   Yes  
          
Notes: *** = p<0.01, ** = p<0.05, * = p<0.10. Robust standard errors adjusted for clustering at the 
birth state level in parentheses. Every row contains a different outcome and the set of controls is 
enlarged in moving from the first to the fifth column. Each estimate is from a different regression and 
is the coefficient on postt*base_pneumonias. The outcome variables are defined in the data appendix. FE 
denotes fixed effects. BaseRate(Control Diseases) includes pre-sulfa birth state averages for maternal 
mortality and mortality from heart disease, cancer, under 2 diarrhea, malaria and tuberculosis. Birth 
State X Birth Year Variables includes per capita log state income, state education expenditure, state 
health expenditure, school buildings, hospitals, and physicians, all by birth state and birth year. Region 
refers to census division region. N refers to the number of birth state x birth year x race x gender x 
census year cells. Each cell is weighted by its population in the regression analysis; unweighted 
regressions produce substantively similar results. 
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Table 2: Additional Disability Variables by Gender 
  
   (1) (2) (3)  (4)  (5) 
All Men                 
Cognitive Disability   -1.4** -1.11**  -0.0315 -2.11  -2.53 
(N =1102, mean = 7.63)  (0.601)  (0.0546)  (0.732)  (1.27)  (1.64) 
          
Physical Disability   -1.23 -0.93  -0.253  -0.789  1.07 
(N =1102, mean = 21.80)  (0.980)  (1.01)  (1.20)  (2.59)  (2.24) 
          
All Women                 
Cognitive Disability   -0.903 -0.731 0.665 2.02*  1.15 
(N = 1118, mean = 6.97)  (0.605)  (0.520)  (0.768)  (1.20)  (1.31) 
          
Physical Disability   -1.04 -0.623 0.596  3.47** 3.13 
(N = 1118, mean =22.70)  (0.886)  (0.882)  (1.11)  (1.52)  (2.01) 
          
See Notes to Table 1. 
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Table 3: Main Results for Men by Race 
   (1)  (2)  (3)  (4)  (5)     (1) (2)  (3)  (4)  (5) 
White Men                  Black Men                 
Work Limiting Disability (%)  -3.161*** -2.890*** -2.089*** -1.327  -3.165*** Work Limiting Disability (%)  -0.187 0.913  0.756  -0.840  0.713 
(N= 1914, mean = 13.44)  (0.650)  (0.561)  (0.651)  (1.055)  (0.806)  (N = 1422, mean = 19.12)  (1.547) (1.284)  (1.598)  (3.499)  (4.095) 
                        
Schooling (Years)  0.401***  0.336***  0.402*** 0.567*** 0.865*** Schooling (Years)  0.380 0.168  -0.153  -0.173  -0.186 
(N = 638, mean=12.58)  (0.107)  (0.0863)  (0.108)  (0.101)  (0.181)  (N = 492, mean=11.54)  (0.302) (0.245)  (0.249)  (0.201)  (0.225) 
                        
Family Income (log)  0.0351** 0.0324** 0.0511*** 0.0703*** 0.111***  Family Income (log)  0.0792 0.0599  0.0110  0.124  0.0223 
(N= 1914, mean = 10.71)  (0.0146)  (0.0127)  (0.0176)  (0.0229)  (0.0306)  (N = 1422, mean = 10.39)  (0.0535) (0.0483)  (0.0597)  (0.111)  (0.0880) 
                        
Poverty (%)  -2.24*** -2.17*** -0.863  -2.27*  -1.22  Poverty (%)  -8.06*** -6.40*** -1.81 -5.72** -3.50 
(N = 1914, mean = 16.70)  (0.565)  (0.530)  (0.804)  (1.14)  (0.893)  (N = 1422, mean = 34.70)  (2.36) (2.03)  (1.80)  (2.59)  (2.23) 
                        
Employment (%)  1.421** 1.388***  2.469***  2.260* 2.855  Employment (%)  3.183 1.669  -1.583  3.315  0.00261 
(N= 1914, mean = 72.52)  (0.636)  (0.504)  (0.564)  (1.204)  (2.004)  (N = 1422, mean = 60.69)  (2.687) (2.623)  (2.378)  (4.328)  (3.778) 
                        
Cognitive Disability  (%)  -1.07 -0.767  0.203 -1.31 -1.32  Cognitive Disability (%)  -5.26*** -5.3*** -4.06* -6.55  -3.56 
(N = 638, mean = 5.99)  (0.658)  (0.622)  (0.750)  (1.26)  (1.89)  (N = 464, mean = 9.89)  (1.55)  (1.78)  (2.27)  (6.07)  (6.23) 
                         
Physical Disability  (%)  -0.932 -0.613 0.132 -0.28  1.46  Physical Disability  (%)  -4.75* -5.66* 1.38 -1.65 1.4 
(N = 638, mean = 18.70)  (1.03)  (1.09)  (1.29)  (2.87)  (2.55)  (N = 464, mean = 26.2)  (2.54)  (3.07)  (4.67)  (5.81)  (8.01) 
                         
See Notes to Table 1. 
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Table 4: Results for Women by Race 
   (1) (2)  (3)  (4)  (5)     (1) (2) (3) (4) (5) 
White Women                  Black Women                 
Work Limiting Disability (%)  -2.736*** -2.288***  -0.618  1.510* 2.225*  Work Limiting Disability (%)  -0.171 0.0956 1.406  1.145  -0.981 
(N= 1914, mean = 11.78)  (0.761) (0.611)  (0.699)  (0.896)  (1.146)  (N = 1464, mean = 19.70)  (1.530) (1.457) (1.384) (3.015) (2.214) 
                    
Schooling (Years)  0.409*** 0.412***  0.261***  -0.0197  -0.0369  Schooling (Years)  0.415 0.271 -0.198 -0.220 -0.381 
(N = 638, mean=12.17)  (0.0854) (0.0774)  (0.0913)  (0.177)  (0.239)  (N = 499, mean=11.64)  (0.345) (0.281) (0.363) (0.293) (0.374) 
                    
Family Income (log)  0.0522*** 0.0502*** 0.0360** -0.0175  0.0212  Family Income (log)  0.0760* 0.0470  0.0190  0.0818  0.118* 
(N= 1914, mean = 10.60)  (0.0163) (0.0138)  (0.0155)  (0.0223)  (0.0335)  (N = 1464, mean = 9.39)  (0.0418) (0.0389) (0.0389) (0.0652) (0.0689) 
                    
Poverty (%)  -3.85*** -3.27*** -1.93* -0.885  -2.09  Poverty (%)  -3.94* -2.51 -0.899  -0.0978  -0.949 
(N = 1914, mean = 20.4)  (0.795) (0.652)  (0.971)  (1.41)  (1.59)  (N = 1464, mean = 42.1)  (2.15) (2.04) (1.93) (2.34) (3.36) 
                    
Employment (%)  -1.536** -1.353**  1.772** 1.577  -0.0399  Employment (%)  3.786** 3.736***  1.389  -4.409  -2.423 
(N= 1914, mean = 52.06)  (0.681) (0.629)  (0.676)  (1.134)  (1.638)  (N = 1464, mean = 52.22)  (1.558) (1.176) (2.044) (2.837) (2.108) 
                    
Cognitive Disability  (%)  -1.09* -0.88*  0.575 1.7  0.773  Cognitive Disability  (%)  0.935 1.23  2.23  1.75 0.543 
(N = 638, mean = 5.00)  (0.626)  (0.515)  (0.696)  (1.26)  (1.64)  (N = 480, mean = 9.59)  (1.77)  (1.81)  (2.70)  (3.43)  (3.37) 
                        
Physical Disability  (%)  -0.891 -0.477 1.44  3.53**  3.62*  Physical Disability  (%)  -2.5 -2.71  -1.95 11.9  6.37 
(N = 638, mean = 18.2)  (0.893)  (0.860)  (1.07)  (1.33)  (2.13)  (N = 480, mean = 28.5)  (3.13)  (3.70)  (3.44)  (9.71)  (7.75) 
Controls                  Controls                 
Birth State, Birth Year FE   Yes   Yes   Yes   Yes   Yes   Birth State, Birth Year FE   Yes  Yes  Yes  Yes  Yes 
Post*BaseRate(Control Diseases)   No   Yes   Yes   Yes   Yes   Post*BaseRate(Control Diseases)   No  Yes  Yes  Yes  Yes 
Birth State X Birth Year Variables   No   No   Yes   Yes   Yes   Birth State X Birth Year Variables   No  No  Yes  Yes  Yes 
Birth State Linear Trends   No   No   No   Yes   Yes   Birth State Linear Trends   No  No  No  Yes  Yes 
Birth Region X Birth Year FE   No   No   No   No   Yes   Birth Region X Birth Year FE   No  No  No  No  Yes 
See Notes to Table 1. 
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Table 5: Triple Difference Estimator by Race and Gender 
 
   Work Disability Schooling Family Income  Poverty  Employment
All Men   -2.332*** 0.254***  0.109***  -1.61* 2.897* 
(N = 3336)  (0.864)  (0.0942)  (0.0191)  (0.884)  (1.606) 
          
All Women   -0.867 0.357*  0.0618***  -2.34  4.484*** 
(N = 6585)  (1.202)  (0.179)  (0.0183)  (1.51)  (1.270) 
          
White Men   -0.847 0.604***  0.125*** 0.771  1.416 
(N = 3807)  (1.173)  (0.153)  (0.0276)  (1.50)  (1.091) 
          
White Women   -0.419 0.373**  0.0551**  -1.64  4.653*** 
(N = 3807)  (1.178)  (0.165)  (0.0207)  (1.40)  (1.342) 
          
Black Men   -7.288*** 0.567  0.0899  -4.31  4.023 
(N = 2665)  (2.648)  (0.515)  (0.0818)  (2.94)  (3.509) 
          
Black Women   -2.558 0.222 0.0846  -5.52  1.385 
(N = 2782)  (2.937)  (0.380)  (0.0637)  (3.63)  (2.360) 
                 
See Notes to Table 1 and Appendix Figure 1. The triple difference term is 
post*base_pneumonia*treated where post and base_pneumonia are defined as in the baseline model and 
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A1: Triple Difference: Treatment Definitions on Cohort and Age of Exposure 
 
 
Notes: Refer section 5.4 of the text. 
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Figure A2. All Men: Birth-Year Specific Coefficients on Pre-Intervention Mortality Rates for Pneumonia and 
Heart Disease 
Work Limiting Disability                                          Schooling 
         
 
Family Income                                                          Poverty 
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Figure A3. All Women: Birth-Year Specific Coefficients on Pre-Intervention Mortality Rates for Pneumonia 
and Heart Disease 
Work Limiting Disability                                        Schooling 
       
 
Family Income                                                        Poverty 





Notes: See Notes to Figure A2.  42 
Appendix Tables 
Table A1: Descriptive Statistics 
Census Variables  Men  Women  White Men  White Women  Black Men  Black Women 
Schooling  12.14 (1.03)  11.94 (0.75)  12.58 (0.78)  12.17 (0.61)  11.54 (1.04)  11.64 (0.80) 
Log Family Income  10.58 (0.44)  10.45 (0.42)  10.72 (0.38)  10.61 (0.33)  10.39 (0.44)  10.23 (0.43) 
Poverty   24.06 (13.26)  29.23 (15.20)  16.56 (5.22)  20.10 (6.01)  34.76 (13.89)  41.93 (14.99) 
% Employed  67.94 (13.26)  52.37(19.05)  72.81 (22.88)  52.35 (17.24)  60.99 (23.60)  52.40 (21.33) 
% Work Disability  15.75 (8.91)  14.93 (9.30)  13.32 (5.08)  11.63 (4.45)  19.22 (11.63)  19.53 (11.97) 
% Cognitive Difficulty  7.55 (6.77)  6.84 (6.40)  5.99 (3.87)  4.95 (2.18)  9.83 (9.08)  9.52 (8.95) 
% Physical Difficulty  21.53 (10.80)  22.24 (10.51)  18.48 (5.64)  17.97 (4.92)  26.013 (0.61)  28.30 (13.04) 
           
Birth State Baseline Mortality Rates (Per Thousand, N = 48 States)         
Pneumonia  1.06  (0.19)         
Tuberculosis  0.64  (0.37)         
Diarrhea  8.22  (5.64)         
Cancer  0.96  (0.31)         
Heart  Disease  2.09  (0.63)         
Maternal mortality   6.35 (1.24)           
Malaria 0.032  (0.074)         
Birth State X Birth Year Socioeconomic Variables (N = 669)         
Log Income Per Capita  6.18 (0.50)           
Log Hospitals Per 1,000  -2.83 (0.46)           
Log Physicians Per 1,000  0.14 (0.36)           
Log Schools Per 1,000  0.72 (0.65)           
Log Educational Spending Per 
Capita 
4.27  (0.79)         
           
Notes: Figures provided are means with standard deviations in parentheses. The means for the census variables are based on the 2019930 men, 2137468 
women, 1821471 white men, 198459 black men, 1897973 white women and 249495 black women born between 1930 and 1943 who are part of the 1980, 
1990 and 2000 5% US census samples available from IPUMS.USA. Census family income figures have been converted to 2000 dollars. Baseline mortality 
rates reflect average mortality rates for each birth state over the period 1930-1936. Rates for pneumonia, tuberculosis, malaria, heart disease and cancer 
reflect deaths per 1,000 total population. Diarrhea and maternal mortality rates are per 1,000 live births.   43 
 
 
Table A2: Placebo Intervention in 1934 
  
Work 
Disability Education Family  Income Poverty 
 
Employment
All Men   1.816** -0.177  -0.000609  1.16  -2.216** 
(N = 3,554)  (0.682)  (0.111)  (0.0194)  (0.935)  (1.052) 
          
All Women   0.189 -0.213***  -0.0209  0.504  -1.363 
(N = 3,582)  (0.682)  (0.0500)  (0.0207)  (0.908)  (0.853) 
          
White Men   1.614* -0.176 0.00811  0.758  -1.532 
(N = 1,914)  (0.874)  (0.118)  (0.0249)  (1.08)  (1.111) 
          
White 
Women   -0.267 -0.279*** -0.0213  -0.0257 -1.268 
(N = 1,914)  (0.581)  (0.0594)  (0.0222)  (1.15)  (1.069) 
          
Black Men   2.825 0.0500  -0.0312  1.90  -4.443 
(N = 1,640)  (2.426)  (0.212)  (0.0598)  (2.91)  (2.675) 
          
Black Women  5.215** 0.202* -0.0560 4.26  -4.435** 
(N = 1,668)  (2.236)  (0.103)  (0.0637)  (2.70)  (1.994) 
                 
See Notes to Table 1. The specification is that in column 5 of Table 1. The placebo involves 
















Table A3: Selective Migration Post-Sulfa 
 
  Fixed effects  Add controls 













Notes: See section 5.4 of the text. The dependent variable is the log of the population aged 20-40. 
Each cell contains the coefficient on post*base_pneumonia from a separate regression. Data are from US 
census microdata files for 1930 and 1940, collapsed to the state level. There are 48 states and the 
maximum number of observations per state is three, denoting population in 1930, 1935 and 1940. The 



































Table A4: Removing the influenza uptick of 1935-1936 
 
   Work  Disability Education Family  Income Poverty    Employment
All Men   -3.037** 0.344** 0.130*** -1.80  3.298* 
( N = 2,851 )  (1.149)  (0.154)  (0.0346)  (1.24)  (1.959) 
          
All Women   2.081** -0.0538 0.0432 -1.67  2.325 
( N = 2,879 )  (1.004)  (0.0914)  (0.0287)  (1.66)  (1.580) 
          
White Men   -3.784*** 0.342** 0.125*** -0.546 2.851 
( N = 1,632 )  (1.192)  (0.162)  (0.0441)  (1.27)  (2.353) 
          
White Women   2.600 -0.0258  0.0614  -2.35  3.482* 
( N = 1,632 )  (1.663)  (0.118)  (0.0412)  (2.01)  (1.938) 
          
Black Men   0.181 0.267 0.124  -9.42**  5.634 
( N = 1,219 )  (4.773)  (0.257)  (0.0845)  (3.96)  (4.893) 
          
Black Women   0.766 -0.0860  -0.0499  1.98  -6.742 
( N = 1,247 )  (4.071)  (0.274)  (0.130)  (5.66)  (5.223) 
                 
See Notes to Table 1. This is the specification in column 5 of Table 1. It is re-estimated 
removing the years 1935-36 from the sample as there was an influenza epidemic in these 

















Disability Education Family  Income Poverty  Employment
All Men   -1.687 0.180*  0.0959***  -1.87*  2.324 
(N = 2,133)  (1.278)  (0.102)  (0.0174)  (0.925)  (1.654) 
          
All Women   0.859 -0.176* 0.0129 -2.32  1.464 
(N = 2,142)  (0.953)  (0.0879)  (0.0193)  (1.59)  (1.921) 
          
White Men   -2.770**  0.191** 0.0909** -1.22 2.956 
(N = 1,158)  (1.057)  (0.0917)  (0.0373)  (0.922)  (2.327) 
          
White Women  2.198 -0.158 -0.0213  -2.99*  2.041 
(N = 1,158)  (1.667)  (0.0990)  (0.0310)  (1.76)  (2.510) 
          
Black Men   0.145 0.109 0.0254  -3.65**  -3.192 
(N = 975)  (4.167)  (0.208)  (0.0937)  (1.75)  (3.113) 
 
Black Women  -3.946 -0.361**  0.0968 -0.0720  -3.089 
(N = 984)  (2.397)  (0.147)  (0.0719)  (3.78)  (2.198) 
 
See Notes to Table 1. This is the specification in column 5 of Table 1. It is re-estimated on a 
sample that excludes the Southern states, namely, Alabama, Arkansas, Delaware, District of 
Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, 
Oklahoma,  South Carolina, Tennessee, Texas, Virginia, West Virginia.  
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Data Appendix 
Outcomes – These were all taken from the 1980 5%, 1990 5% and 2000 5% United States 
Census Microdata samples (available via IPUMS-USA, http://usa.ipums.org/usa/). These 
data are publicly available via the Integrated Public Use Microdata Series – USA project 
(Ruggles et al., 2010). We aggregated all data into birth state X birth cohort X race (white 
and other) X gender X census year cells. Data on the 2,019,930 men, 2,137,468 women, 
1821,471 white men, 198,459 black men, 1,897,973 white women and 248,495 black women 
in the three census samples who were born between 1930 and 1943 (the period of interest in 
the study) were used to create cell level means. 
 
Schooling  – Represents the highest grade of schooling completed. This variable was 
constructed using the IPUMS variable HIGRADE. The 1980 census provides explicitly 
designated years of schooling for the pre-high school years. Later census files  group those 
completing ninth grade and under into three categories and top code those who progress 
beyond college. Since schooling was likely completed before the age of 30 for most sample 
individuals, we show estimates that use only the 1980 census data for this variable. 
 
Logged Total Family Income – From the IPUMS variable FTOTINC. Describes the (nominal) 
total pre-tax money income earned by the respondent’s family unit in the previous calendar 
year. 
 
Poverty- An indicator for whether family income is 200% below the federal household 
poverty line or lower. 
 
Employed  - Uses the IPUMS variable EMPSTAT, which distinguishes between current 
employment, unemployment and not being in the labor force. For each individual, we set 
employment = 1 if the individual reports current employment and 0 otherwise. 
 
Work Limiting Disability – The IPUMS variable DISABWRK Indicates a physical or mental 
health condition that causes difficulty working, limits the amount or type of work, or 
prevents working altogether. The disability cannot be transient (e.g., pregnancy) and must 
have been present for at least six month prior to survey. We coded any limitation in the 
ability to work (either certain limitations or the inability to work altogether) as representing 
disability. 
 
Cognitive Disability – From the IPUMS variable DIFFREM, which denotes whether an 
individual has difficulty with cognitive tasks due to a physical or mental illness. This variable 
is only available in the 2000 census. 
 
Physical Disability – From the IPUMS variable DIFFPHYS. Denotes if the respondent has a 
condition that limits basic tasks of daily living that involve movement (walking, running, 
lifting, etc). This variable is only available in the 2000 census.  
 
Mortality rates by cause of death – State time series data on influenza and pneumonia, 
under-2 diarrheal, heart disease, cancer, and tuberculosis mortality, as well as the maternal 
mortality ratio, were taken from various volumes of the US Vital Statistics (Grove, 1968;   48
Linder, 1947; United States Bureau of the Census, 1930-1943). We also made use of US Vital 
Statistics data collected by Grant Miller and Seema Jayachandran, Adriana Lleras-Muney, and 
Kimberly Smith
32 and we obtained the malaria data from the NBER. We used these data to 
create state-specific pre-sulfa rates for each disease by averaging the mortality rate between 
1930 and 1936. In section 3 of the text we argue that pneumonia dominates in the combined 
category and that declines in influenza and pneumonia are largely driven by declines in 
pneumonia. We also used race specific state mortality data which Adriana Lleras-Muney 
generously provided. They are from yearly US Vital Statistics volumes 
(http://www.cdc.gov/nchs/products/vsus.htm).  
 
Socioeconomic Characteristics and Infrastructure Variables – State time series data on 
logged state per capita income were taken from the Bureau of Economic Analysis website 
(http://www.bea.gov/regional/spi/). Data on the number of schools, doctors, hospitals, 
and educational expenditures per capita were taken from Adriana Lleras-Muney’s website 
(http://www.econ.ucla.edu/alleras/research/data.html). These data were originally collected 
from various volumes of the Biennial Survey of Education (schools and expenditures) and the 
American Medical Association’s American Medical Directory (doctors and hospitals). We used 
linear interpolation for each state to calculate education and health infrastructure values for 
1940-1943, as Lleras-Muney’s data was only collected through 1939. For state per capita 
health expenditures, we used data collected by Sylla, et al from various reports from the US 
Census bureau. For the study period of interest, this data source had information for 1932, 
so we used data for that year, interacted with post in our regression models. This data can be 











                                                 
32http://www.nber.org/data/vital-statistics-deaths-historical/), 
(http://www.aeaweb.org/articles.php?doi=10.1257/app.2.2.118) 